ReviewNature reviews. Rheumatology2019
Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.
Review in Nature reviews. Rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07443956 (Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis), which is not on this map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.Annals of the rheumatic diseases · 2024Guideline
- [Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020].Zeitschrift fur Rheumatologie · 2020Guideline
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.Annals of the rheumatic diseases · 2020Guideline
- Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.Annals of the rheumatic diseases · 2022Trial
- Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Body Mass Index Is Associated with the Immunometabolic Profile in Psoriatic Arthritis: Real-Life Data.Diseases (Basel, Switzerland) · 2026Article
- Comorbidity Profiles at Diagnosis in Rheumatoid Arthritis Versus Psoriatic Arthritis: A Nationwide Polish Claims-Based Study.Journal of clinical medicine · 2026Article
- Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.International journal of molecular sciences · 2026Review
- Cognitive impairment risk in patients with rheumatoid arthritis: a population-based cohort study.RMD open · 2026Article
- The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.EULAR rheumatology open · 2026Article
- Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK.Rheumatology advances in practice · 2026Article
- Tuberculosis incidence in patients treated with secukinumab - a real-world study in Brazil.Advances in rheumatology (London, England) · 2025Article
- The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- A western diet amplified the deleterious consequences of collagen-induced arthritis on cardiac homeostasis in female rats.Journal of physiology and biochemistry · 2025Article
- Increased risk of major adverse cardiovascular events in patients with deep and infected diabetes-related foot ulcers.Diabetologia · 2025Article
- Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events.Dermatology and therapy · 2025Article
- Association between the triglyceride-glucose-waist-to-height ratio and cardiovascular disease in Chinese adults with sarcopenia or probable sarcopenia.Frontiers in endocrinology · 2025Article
- Therapeutic strategy in psoriatic arthritis: choosing the right treatment for the right patient.Therapeutic advances in musculoskeletal disease · 2025Article
- The risk of interstitial lung disease in psoriatic arthritis versus psoriasis: a retrospective nationwide database analysis (2014-24).Rheumatology advances in practice · 2025Article
- Disease burden in inflammatory arthritis: an unsupervised machine learning approach of the COVAD-2 e-survey dataset.Rheumatology advances in practice · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cardiometabolic comorbidities present a considerable burden for patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA). Both RA and PsA are associated with an increased risk of cardiovascular disease (CVD). PsA more often exhibits an increased risk of metabolically linked comorbidities such as obesity, insulin resistance, type 2 diabetes mellitus and non-alcoholic fatty liver disease. Although both RA and PsA are characterized by a state of chronic inflammation, the mechanisms that contribute to CVD risk in these conditions might not be identical. In RA, systemic inflammation is thought to directly contribute to CVD risk, whereas in PsA, adiposity is thought to contribute to a notable metabolic phenotype that, in turn, contributes to CVD risk. Hence, appropriate management strategies that consider the increased risk of cardiometabolic comorbidities in patients with inflammatory arthropathy are important. In RA, such strategies should focus on the prediction of CVD risk and its management through targeting chronic inflammation and traditional CVD risk factors. In PsA, management strategies should additionally focus on targeting metabolic components, including weight management, which might not only help improve disease activity in the joints, entheses and skin, but also reduce the risk of metabolic comorbidities and improve the quality of life of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.